Avio Smart Market Stack Limited (formerly known as Bartronics India Limited) has announced a strategic equity investment of ₹7.50 crore in Huwel Lifesciences Private Limited, marking a significant expansion into the molecular diagnostics sector. The investment was disclosed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investment Details

The company has acquired 9,665 equity shares of Huwel Lifesciences at a price of ₹7,760 per share, which includes a substantial premium of ₹7,750 per share. This investment represents 2.11% of the paid-up equity share capital of Huwel Lifesciences.

About Huwel Lifesciences

Huwel Lifesciences Private Limited is a specialized company operating in the lifescience and health sector. Incorporated on February 10, 2015, with CIN U33111TG2015PTC097596, the company is headquartered in Patancheru, Telangana, India. The target entity focuses on the development, manufacturing, and supply of molecular diagnostic kits, medical devices, and in-vitro diagnostic solutions.

The company serves a diverse clientele including hospitals, laboratories, and research institutions by providing essential products for disease detection and healthcare testing. This positions Huwel Lifesciences as a key player in India's growing diagnostics market.

Financial Performance

Huwel Lifesciences has demonstrated variable financial performance over the past three years:

Strategic Rationale

The acquisition is designed to derive operational and financial synergies for Avio Smart Market Stack Limited. The company has confirmed that this transaction does not fall within the ambit of related party transactions, and the promoter/promoter group/group companies have no interest in the target entity. The acquisition has been conducted on an arm's length basis, ensuring transparency and fair valuation.

Transaction Structure

The investment represents the completion of the first tranche, with remaining tranches to be completed in accordance with the terms and conditions specified in the Shareholders' Agreement. No governmental or regulatory approvals are required for this acquisition, streamlining the investment process.

This strategic investment aligns with Avio Smart Market Stack Limited's diversification strategy and positions the company to benefit from the growing demand for molecular diagnostics and healthcare testing solutions in India.

Avio Smart Market Stack Limited has announced the completion of a strategic equity investment worth INR 1 crore in Shree Naganarasimha Private Limited (SNN), marking a significant expansion into the agro and food products sector. The investment was disclosed under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Investment Details

The company has acquired substantial stake in the target entity through a carefully structured transaction:

Target Company Profile

Shree Naganarasimha Private Limited, incorporated on December 24, 2022, operates in the manufacturing and trading of agro and food products. The company is engaged in comprehensive food processing activities including:

• Processing, producing, mixing, packing, and preserving food products
• Manufacturing of processed foods, beverages, and dry foods
• Trading in health foods, protein foods, and agro foods
• Import and export of various food products and beverages
• Dealing in vegetables, fruits, and nutrient-based food items

Financial Performance

SNN has demonstrated impressive growth trajectory since its incorporation, showing consistent revenue expansion:

The company's turnover has grown significantly from INR 1.39 crore in FY23 to INR 11.48 crore in FY25, reflecting strong business momentum in the agro-food sector.

Strategic Rationale

The acquisition is designed to derive operational and financial synergies between both entities. The investment does not fall within related party transactions, and the promoter group has no existing interest in the target entity. This represents the first tranche of the investment, with remaining tranches to be completed according to the Shareholders' Agreement terms.

Regulatory Compliance

The transaction has been structured in full compliance with regulatory requirements, with no additional governmental or regulatory approvals needed for completion. The company has maintained transparency through proper disclosure under SEBI regulations, following previous intimations dated January 08, 2026, January 23, 2026, and February 16, 2026.